Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Peter Kyle calls on employees and businesses to act now to get to grips with technology amid forecasts of job losses.
Breakthroughs such as the emergence of ChatGPT have sparked an investment boom in the technology, but also led to forecasts that…
The company will use the funds to increase the adoption of its new offering, Sage, across healthcare providers, payers and care management organizations.
Ellipsis Health, a company using AI voice agent technology, announced it has raised $45 million in a new…
Attendees
Sponsors and Exhibitors
Contact us